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Background: Vemurafenib, an inhibitor of genetically activated BRAF, is now commonly prescribed for metastatic
melanoma harboring a BRAF mutation. Reports on side effects have focused on cutaneous complications. We here
present a case of a severe pan-uveitis associated with vemurafenib use.
Case presentation: A 63-year old female was treated with the BRAF inhibitor vemurafenib for metastatic
melanoma. After seven weeks of treatment, she developed near-complete visual loss in the course of a few days, as
a result of severe uveitis. Vemurafenib had to be discontinued and systemic and topical corticosteroids were
initiated. The visual symptoms improved slowly, however the cerebral metastases progressed and the patient died
from her disease.
Conclusion: Treatment with vemurafenib has become an important component of standard clinical care for
patients with metastatic melanoma. In addition, it is one of the best examples of genotype-directed therapy. This
case illustrates that vemurafenib-induced uveitis can develop fast and be slow to resolve. Awareness of this
potentially severe side effect is of major importance to oncologists and aggressive treatment should be considered.
Keywords: Melanoma, Uveitis, Vemurafenib, BRAFBackground
Until very recently, treatment options for metastatic
melanoma were virtually non-existent. This situation has
dramatically changed with the introduction of the BRAF
inhibitors vemurafenib [1] and dabrafenib [2] and the
anti-CTLA4 antibody ipilimumab [3,4]. Additionally,
promising therapeutic strategies currently in phase 3 tri-
als include combinatorial approaches of BRAF inhibitors
with MEK inhibitors [5] and anti-PD1 and anti-PD-L1
antibodies [6]. Side effects of these new classes of thera-
peutics are very different from traditional chemotherapy,
as has been particularly noted for ipilimumab [7]. Side
effects of vemurafenib are generally of low to moderate
severity and include arthralgia, rash, fatigue, photosensi-
tivity and keratoacanthoma or squamous cell carcinoma
of the skin [1]. We present a case of a patient on vemur-
afenib with near-complete visual loss caused by a
pan-uveitis.* Correspondence: MS.vd.Heijden@nki.nl
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A 63-year old female presented with weakness of her left
leg. She had been treated in 2001 for a superficially
spreading melanoma, Breslow depth 1.4 mm. Magnetic
Resonance Imaging (MRI) of the brain revealed a metas-
tasis in the right frontal lobe with signs of hemorrhage
and several additional small cerebral metastases. Subse-
quent computed tomography (CT) scans showed metas-
tases to the thoracic and lumbar spine. A biopsy of a
metastasis at the sacro-iliac joint revealed melanoma
cells; mutation analysis of the BRAF gene showed a
V600E mutation in exon 15. Initial treatment consisted
of whole-brain radiation (7×4 Gy), and radiation to the
thoracic and lumbar spine. Since all of the known me-
tastases had been treated with radiation, systemic treat-
ment was not initiated yet.
A CT scan made two months later revealed new metasta-
ses in the right lung, peritoneum and left groin. The patient
had recovered well from the cerebral hemorrhage and the
treatment of her cerebral and spinal metastases. She was
able to walk for a short distance and her only complaint
was a moderate hearing loss. MR imaging of the brain re-
vealed a slight decrease of the cerebral hemorrhage and nod. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Gadolinium-enhanced T1-weighted magnetic resonance images of cerebral metastases. A. MRI of the brain before treatment
with vemurafenib. B. MRI at presentation with visual loss. C. MRI four weeks after cessation of treatment.
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of the BRAF kinase, was initiated at 960 mg bi-daily. Treat-
ment was initially tolerated well except for mild periorbital
edema.
After seven weeks of treatment with vemurafenib, she
presented to the hospital with severe visual loss, which had
started several days earlier. She did not have a previous
medical history of ocular problems. An MRI of the brain
showed less hemorrhage of the right frontal metastasis and
no increase in size of the other small cerebral lesions
(Figure 1B). A CT scan showed regression of the peritoneal
and pulmonary lesions and stabilization of the metastasis to
the right groin. Ophthalmological examination revealed a
visual acuity of only light perception in both eyes. Slit lamp
examination showed shallow anterior chambers in both
eyes, and a severe fibrinous and cellular reaction, covering
the entire pupillary opening and causing a pupillary block
and secondary elevation of the ocular pressure (Figure 2).
Ultrasound imaging of the eyeball showed signs of scleritis.
Vemurafinib was considered the culprit and therefore dis-
continued; treatment with topical and systemic coricoster-
oids (prednisone, 60 mg per day) was initiated. The
patient’s scleritis decreased and her vision improved slowlyFigure 2 Uveitis with cells in the shallow anterior chamber. Slit lamp e
cellular reaction, covering the entire pupillary opening.to a visual acuity of 0.25 in the right and 0.8 in the left eye.
At that time, fundoscopic examination was possible, and
did not reveal signs of vasculitis nor chororetinitis in both
eyes. A surgical peripheral iridectomy was performed in the
right eye to reverse a pupillary block caused by posterior
synechiae.
Four weeks after cessation of treatment, she presented
with progressive aphasia. An MRI of the brain showed pro-
gression of cerebral metastases with new hemorrhages in
several metastases (Figure 1C). At that moment, her vision
had improved, but had still not fully recovered. Because of
the severe impact of the visual loss on quality of life, and
since the response of the cerebral metastases at 7 weeks of
treatment with vemurafenib showed stabilization at best, a
second attempt of treatment with BRAF inhibitors was not
initiated. Second line treatment with ipilimumab, an anti-
CTLA4 antibody, was considered. The occurrence of a se-
vere pan-uveitis was judged to be a contraindication to
therapy that acts by stimulating the immune system. Add-
itionally, she was still being treated with systemic cortico-
steroids. Dacarbazine was considered, but viewed as a
treatment with little chance of response in this setting. The
patient and her family preferred to refrain from furtherxamination: shallow anterior chambers and a severe fibrinous and
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weeks later.
Conclusions
We here present a case of severe vemurafenib-
induced uveitis, with near-complete visual loss devel-
oping in the course of only a few days. Mild cases of
uveitis have been noted in the original phase III trial
[1] (product insert; 2,1%) and were reported in a re-
cent poster abstract from an Australian ocular clinic
in 23/516 (4.5%) of patients treated with vemurafenib
[8]. These cases usually resolved with topical cortico-
steroids, while continuing vemurafenib. This is the
first report to our knowledge of a vemurafenib-
induced pan-uveitis leading to near-complete visual
loss.
Uveitis is the process of intraocular inflammation
and may result from different causes: infections,
systemic immune-mediated disease, and masquerade
syndromes. Pan-uveitis is defined as simultaneous in-
flammation in the anterior chamber, vitreous humor,
and retina or choroid. Slit lamp and fundoscopic
examination are necessary to establish the presence of
uveitis. Drug-induced uveitis is a rare clinical condi-
tion [9]. A wide range of medications can cause drug-
induced uveitis, as for example rifabutin. A recent re-
view by London et al. [10] summarized that the
underlying mechanism of drug-induced uveitis is still
mostly unclear and that both inflammatory and toxic
reactions may play a role. An immunologic cross-
reaction between vemurafenib and antigens in the
uvea could play a role, however this remains
speculative.
Drug-induced uveitis is usually reversible within
weeks of discontinuation of the offending drug. Non-
infectious causes of anterior uveitis are in general
treated with topical glucocorticoids several times a
day. Oral glucocorticoids are reserved for patients
with bilateral disease or for patients who do not
respond to topical medications. The role of tumor
necrosis factor-alpha (TNF-α) inhibitors in the treat-
ment of patients with uveitis is being investigated
[11]; these inhibitors appear to be more effective than
corticosteroids in some patients with noninfectious
uveitis [12]. In the case of metastatic melanoma, reso-
lution of symptoms is pivotal to initiate a new line of
treatment. This would argue in favor of aggressive
treatment early in a case of severe uveitis, with
systemic corticosteroids and possibly anti-TNF-α
blockade.
Reports on side effects of vemurafenib have so far fo-
cused on cutaneous findings. One of the most concerning
side effects is the development of cutaneous malignancies,
primarily well-differentiated squamous cell carcinomas(SCC) and keratoacanthomas (KA), which occur in up to
25% of vemurafenib users [13]. Now that vemurafenib has
become a component of the routine clinical treatment of
metastatic melanoma, awareness of rare but severe side ef-
fects of this drug is of major importance to clinicians. This
case illustrates a potentially severe ocular side effect in pa-
tients treated with vemurafenib.
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